ARGX

argenx SE

362.44 USD
-15.34 (-4.06%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

argenx SE stock is down -3.48% since 30 days ago. The next earnings date is Jul 25, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 57.14% of the previous 7 May’s closed higher than April. In the last 10 Unusual Options Trades, there were 7 CALLs, 3 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
17 May 14:30 19 Jul, 2024 420.00 CALL 63 0
17 May 14:51 21 Jun, 2024 370.00 PUT 20 44
20 May 13:30 19 Jul, 2024 420.00 CALL 40 63
21 May 17:35 17 Jan, 2025 350.00 PUT 10 20
21 May 19:55 21 Jun, 2024 370.00 CALL 17 32
21 May 19:56 21 Jun, 2024 370.00 CALL 47 32
22 May 14:27 21 Jun, 2024 370.00 CALL 15 130
28 May 18:14 19 Dec, 2025 300.00 CALL 8 0
29 May 14:27 21 Jun, 2024 430.00 CALL 60 130
30 May 13:30 16 Aug, 2024 370.00 PUT 11 11

About argenx SE

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases. Its lead product candidate is efgartigimod for the. treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS.

  • Morgan Stanley
    Tue May 28, 13:20
    buy
    confirm
  • JP Morgan
    Mon May 13, 10:24
    buy
    confirm
  • HC Wainwright & Co.
    Fri May 10, 15:31
    buy
    confirm
  • JP Morgan
    Fri May 10, 12:41
    buy
    confirm